Clovis Oncology (CLVS) Misses Q2 EPS by 6c

Clovis Oncology (NASDAQ: CLVS) reported Q2 EPS of ($1.94), $0.06 worse than the analyst estimate of ($1.88). Revenue for the quarter came in at $23.76 million versus the consensus estimate of $22.44 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BofA Securities Downgrades Autohome Inc. (ATHM) to Underperform
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c